CN1390127A - 含有伊曲康唑的抗真菌口服组合物及其制备方法 - Google Patents

含有伊曲康唑的抗真菌口服组合物及其制备方法 Download PDF

Info

Publication number
CN1390127A
CN1390127A CN00808948A CN00808948A CN1390127A CN 1390127 A CN1390127 A CN 1390127A CN 00808948 A CN00808948 A CN 00808948A CN 00808948 A CN00808948 A CN 00808948A CN 1390127 A CN1390127 A CN 1390127A
Authority
CN
China
Prior art keywords
itraconazole
mixture
composition
phosphoric acid
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00808948A
Other languages
English (en)
Other versions
CN1170539C (zh
Inventor
禹钟守
李鸿基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Industries Co Ltd
Publication of CN1390127A publication Critical patent/CN1390127A/zh
Application granted granted Critical
Publication of CN1170539C publication Critical patent/CN1170539C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

含有伊曲康唑和磷酸的熔凝混合物的抗真菌口服组合物可以达到很高的伊曲康唑体内生物利用度。

Description

含有伊曲康唑的抗真菌口服组合物及其制备方法
发明领域
本发明涉及具有改善的伊曲康唑(itraconazole)生物利用度的伊曲康唑的口服组合物及其制备方法。
发明背景
伊曲康唑是一种三唑化合物，已知它具有优良的抗真菌活性。但是，口服给药伊曲康唑的生物利用度非常低，因为它在水中的溶解度很低，不到1μg/ml，并且由于它的pKa值为3.7，因此在胃液中仍保持未电离的状态。此外，已知口服给药伊曲康唑的生物利用度在个体之间有很大差异，并且还取决于摄入的食物等其它因素。
PCT国际申请公开号WO 85/02767和美国专利4,764,604教导了一种通过使用伊曲康唑的环糊精包合物来增加伊曲康唑溶解度的方法。但是，该方法的问题是伊曲康唑溶解度的增加并不明显，并且还需要各种复杂的制备方法。
最近，PCT国际申请公开号WO 94/05263公开了一种包衣珠制剂，其中，将由药物惰性或中性的蔗糖、糊精、淀粉等制成的核芯用伊曲康唑和亲水性聚合物的混合物包衣，然后，将形成的珠再次用聚合物例如聚乙二醇包衣。该包衣珠制剂可以从Janssen Pharmaceutica(Beerse，Belgium)以Sporanox胶囊的商标名购买到。但是，上述制剂的生产方法非常复杂，因为平均直径仅有600至700μm的小珠在生产过程中会趋向于形成大块。
PCT国际申请公开号WO 97/44014公开了一种伊曲康唑在水溶性聚合物中的固体分散体，该分散体通过将伊曲康唑和水溶性聚合物的混合物在245℃至265℃的温度范围内进行熔融挤出过程制得。据称该固体分散体具有改善的伊曲康唑的生物利用度，其生物利用度不受摄入的食物的影响，并且可以从Janssen Pharmaceutica(Beerse，Belgium)以Sporanox片剂的商标名购买到。但是，固体分散体的生产方法受到在控制各种方法可变参数时的许多困难的限制，并且上述分散体所能达到的伊曲康唑的体内生物利用度仍然很低。
因此，仍需要开发一种具有改善的伊曲康唑体内生物利用度的口服组合物。
发明概述
因此，本发明的目的是提供一种含有伊曲康唑的改进了的口服组合物。
本发明的另一个目的是提供制备所述口服组合物的方法。
根据本发明的一个方面，本发明提供了用于口服给药的抗真菌组合物，该组合物含有伊曲康唑和磷酸、可药用载体和表面活性剂的熔凝混合物(fused mixture)。
附图概述
通过以下对本发明的描述并结合附图，可以清楚地看出本发明的上述和其它目的及特点，其中：
图1显示了本发明的伊曲康唑制剂和市售的伊曲康唑制剂的生物利用度。
发明详述
在整个说明书中，通过将伊曲康唑和磷酸熔融形成熔化物然后将该熔化物冷却所得到的固体均称为伊曲康唑和磷酸的熔凝混合物。该混合物的熔点远远低于伊曲康唑，并且与固体伊曲康唑相比，伊曲康唑从所述混合物到水溶液中的溶出有了很大的提高，从而增加了伊曲康唑的体内生物利用度。
在本发明的熔凝混合物中，伊曲康唑和磷酸的重量比为1∶0.1至1∶10，优选1∶0.5至1∶5。
含有伊曲康唑和磷酸的熔凝混合物的本发明组合物可以含有可药用载体，例如乳糖、糊精、淀粉、微晶纤维素、羟丙甲基纤维素、羟丙基纤维素、羟乙基纤维素、乙基纤维素、甲基纤维素、聚乙二醇、二氧化硅、水滑石、硅酸镁铝(aluminum magnesium silicate)、氢氧化铝、硅酸铝、硅酸镁铝(magnesium aluminum metasilicate)、膨润土及其混合物。
本发明的抗真菌口服组合物还可以含有表面活性剂，它可以促进伊曲康唑和磷酸的熔凝混合物在含水溶媒中的润湿。表面活性剂的代表性例子包括：
(1)聚氧乙烯乙二醇化(polyoxyethylene glycolated)的天然或氢化植物油例如聚氧乙烯乙二醇化的天然或氢化蓖麻油(Cremophor，BASF)，
(2)聚氧乙烯-脱水山梨醇-脂肪酸酯，其中的脂肪酸是单-或三-月桂酸、棕榈酸、硬脂酸、油酸(Tween，ICI)，
(3)聚氧乙烯脂肪酸酯，例如聚氧乙烯硬脂酸酯(Myrj，ICI)，
(4)聚氧乙烯-聚氧丙烯嵌段共聚物(Poloxamer，BASF)，
(5)二辛基磺基琥珀酸钠或十二烷基硫酸钠，
(6)磷脂，
(7)丙二醇单-或二-脂肪酸酯，例如丙二醇二辛酸酯、丙二醇二月桂酸酯、丙二醇异硬脂酸酯、丙二醇月桂酸酯、丙二醇蓖麻油酸酯、丙二醇辛酸-癸酸二酯(Miglyol840，Huls)，
(8)天然植物油甘油三酯和聚亚烷基多元醇的反式酯化的产物(LabrafilM，Gattefosse)，
(9)单-、二-或单/二-甘油酯，例如辛酸/癸酸单-和二-甘油酯(Imwitor，Huls)，和
(10)脱水山梨醇脂肪酸酯，例如脱水山梨醇单月桂酸酯、脱水山梨醇单棕榈酸酯和脱水山梨醇单硬脂酸酯(Span，ICI)。
在上述表面活性剂中，本发明优选使用聚氧乙烯乙二醇化的天然或氢化植物油、聚氧乙烯-脱水山梨醇-脂肪酸酯和聚氧乙烯-聚氧丙烯嵌段共聚物。
此外，根据本发明的另一方面，本发明提供了制备本发明组合物的方法，该方法包括，(a)将伊曲康唑和磷酸混合，(b)将混合物加热至100至170℃得到均匀的熔融(melt)混合物，(c)向其中加入可药用载体和表面活性剂，(d)将形成的混合物冷却得到固体，和(e)将固体粉碎。
或者，本发明的组合物可以用有机溶剂例如乙醇、二氯甲烷和氯仿来制备。具体地讲，将伊曲康唑与磷酸混合然后向形成的混合物中加入少量有机溶剂得到溶液。随后，向其中加入可药用载体和表面活性剂，将形成的溶液加热蒸除溶剂然后冷却得到固体，然后将固体粉碎。
可以按照常规方法将本发明的药物组合物制成各种药物制剂，例如散剂、颗粒剂、片剂、包衣的制剂和液体制剂。例如，硬胶囊可以通过如下方法制备：向药物组合物中加入润滑剂和其它药物添加剂，将混合物加工成粉末或颗粒，然后将粉末或颗粒填充到硬明胶胶囊中；片剂可以通过向药物组合物中加入适宜的添加剂然后将混合物压片来制备；液体制剂可以通过将药物组合物溶于水中来制备；包衣的制剂可以通过将药物组合物的溶液涂覆在糖珠例如Non-pareil(Edward Mendell Co.，UK)上来制备。
如上所述，含有伊曲康唑和磷酸的熔凝混合物的本发明组合物可以达到很高的伊曲康唑体内生物利用度。此外，本发明的制备含有伊曲康唑的本发明抗真菌组合物的方法与现有技术方法相比的优点在于它的加工温度较低而生产效率很高。
以下实施例是用来进一步说明本发明的，并不限定本发明的范围。
此外，以下给出的固体在固体混合物中、液体在液体中以及固体在液体中的百分比分别是基于wt/wt、vol/vol和wt/vol，除非另有具体说明。实施例1：硬胶囊的制备
用如下成分制备硬胶囊：
                                                   量(mg/胶囊)
伊曲康唑                                             100
磷酸85％                                             150
Poloxamer407                                      30
CremophorRH40                                     10
羟丙甲基纤维素                                       20
水滑石                                               70
二氧化硅                                             20
将伊曲康唑和磷酸混合并将混合物加热至160℃得到熔化了的熔化物。在使混合物冷却的同时向其中加入除二氧化硅之外的其它成分。然后，将形成的混合物冷却至室温得到熔凝的固体。将固体与二氧化硅混合，粉碎然后填充到硬明胶胶囊中。实施例2：硬胶囊的制备
用如下成分通过实施例1的方法制备硬胶囊：
                                                量(mg/胶囊)
伊曲康唑                                          100
磷酸85％                                          100
Poloxamer407                                   30
Tween80                                        10
羟丙甲基纤维素                                    20
水滑石                                            70
二氧化硅                                          20实施例3：硬胶囊的制备
用如下成分通过实施例1的方法制备硬胶囊：
                                                量(mg/胶囊)
伊曲康唑                                          100
磷酸85％                                          100
Poloxamer407                                   30
CremophorRH40                                  10
水滑石                                            100
二氧化硅                                          20实施例4：硬胶囊的制备
用如下成分通过实施例1的方法制备硬胶囊：
                                                 量(mg/胶囊)
伊曲康唑                                           100
磷酸85％                                           150
Tween80                                         20
CremophorRH40                                   10
水滑石                                             70
二氧化硅                                           20实施例5：硬胶囊的制备
用如下成分通过实施例1的方法制备硬胶囊：
                                                量(mg/胶囊)
伊曲康唑                                          100
磷酸85％                                          50
Poloxamer407                                   40
CremophorRH40                                  20
水滑石                                            70
二氧化硅                                          20实施例6：硬胶囊的制备
用如下成分通过实施例1的方法制备硬胶囊：
                                                量(mg/胶囊)
伊曲康唑                                          100
磷酸85％                                          150
Poloxamer407                                   30
CremophorRH40                                  10
聚乙二醇(PEG)20000                                150
二氧化硅                                          20实施例7：硬胶囊的制备
用如下成分制备硬胶囊：
                                                量(mg/胶囊)
伊曲康唑                                          100
磷酸85％                                          100
乙醇                                              500
Poloxamer407                                   100
CremophorRH40                                  50
聚乙二醇(PEG)20000                                200
将伊曲康唑和磷酸混合，向混合物中加入乙醇得到溶液。向其中加入其它成分，将形成的溶液加热至100℃蒸除乙醇，然后冷却至室温得到固体。将固体粉碎然后填充到硬明胶胶囊中。实施例8：含有包衣珠的硬胶囊的制备
用如下成分制备含有包衣珠的硬胶囊：
                                                量(mg/胶囊)
伊曲康唑                                          100
磷酸85％                                          200
乙醇                                              500
聚乙二醇(PEG)20000                                  100
CremophorRH40                                    20
糖珠                                                400
用实施例7的方法制备含有除乙醇之外的其它成分的混合物，其中含有一半的PEG 20000。将混合物均匀地涂覆在糖珠上，然后在其上涂覆剩余部分的PEG 20000。然后将制得的包衣糖珠填充到硬明胶胶囊中。比较实施例：硬胶囊的制备
按照实施例1的方法用如下成分制备硬胶囊，但不使用磷酸：
                                                量(mg/胶囊)
伊曲康唑                                          100
Poloxamer407                                   30
CremophorRH40                                  10
羟丙甲基纤维素                                    20
水滑石                                            70
二氧化硅                                          20试验实施例1：溶解试验
按照《韩国药典》的“一般试验”一章中描述的溶出试验方法II(桨法)在下述条件下测定本发明实施例1至3的制剂；比较实施例的制剂；Sporanox胶囊和Sporanox片剂(Janssen Korea)的伊曲康唑溶出速率：
试验装置：Erweka DT80(Erweka，德国)
试验溶液：900ml 0.1N HCl
试验溶液的温度：37±0.5℃
旋转速度：100±4rpm
分析方法：液相色谱
-柱：Cosmosil C18(150mm×4.6mm；Nacalai tesque，日本)
-流动相∶乙腈/磷酸盐缓冲液(pH 7.0)＝60∶40
-流速：1.2ml/分钟
-检测器：UV 255nm
-注射体积：10μl
溶出的伊曲康唑的量用45分钟内洗脱的伊曲康唑的累积量表示，结果如表1中所示。
                                   表1
    样品 实施例1 实施例2   实施例3     比较实施例 Sporanox胶囊 Sporanox片剂
  溶出的量(45分钟)   94％   91％   96％     15％     50％     92％
从表1可以看出，实施例1至3的制剂显示出明显高于比较实施例和Sporanox胶囊的伊曲康唑的溶解量。该结果证实，通过使用本发明的伊曲康唑和磷酸的熔凝混合物可以大大提高伊曲康唑在水中的溶解度。
此外，虽然Sporanox片剂显示出类似于实施例1至3的伊曲康唑的高水平溶出，但本发明制剂的生产方法比Sporanox片剂简单得多，并且生产效率更高。此外，如试验实施例2所示，Sporanox片剂的伊曲康唑体内生物利用度显著低于本发明的组合物。试验实施例2：体内吸收试验
为了研究本发明制剂中所含的伊曲康唑的生物利用度，进行了如下体内吸收试验。
将30只体重均为大约300g的14或15周龄的雄性Sprague-Dawly大鼠禁食48小时并同时可以使其随意地接近水，然后将其分成每组含10只大鼠的两组。
向两组大鼠分别口服给药本发明实施例1的制剂和Sporanox片剂，剂量为20mg伊曲康唑/kg大鼠体重。在给药前和给药2、4、6、8和24小时后直接从大鼠的心脏获取血样，然后从其中分离出血清。
向500μl各血清样品中加入50μl内标物溶液(含有500μg/ml益康唑的甲醇溶液)和200μl 1M碳酸盐缓冲液(pH 10.0)。向其中加入7ml提取溶剂(正庚烷∶异戊醇＝9∶1)并将形成的混合物于80rpm振摇5分钟得到提取物。将提取物以3,000rpm离心10分钟，然后在氮气氛下于50℃蒸除溶剂。向形成的残余物中加入200μl 0.05％三乙胺的65％含水乙腈溶液并将该混合物在如下条件下进行HPLC：
-柱：Inertsil ODS2(250×4.6mm，5μm；GL科学，日本)
-流动相：含有0.05％三乙胺的65％乙腈水溶液
-检测器：UV 258nm
-流速：1.2ml/分钟
-注射体积：100μl
表1中的结果证实，用本发明制剂所观察到的伊曲康唑的生物利用度远远高于Sporanox片剂。
虽然就上述具体实施方案对本发明进行了描述，但应当理解，本领域技术人员可以对本发明进行各种修饰和改变，这些修饰和改变也落在所附权利要求所定义的本发明的范围之内。

Claims (5)

1.用于口服给药的抗真菌组合物，该组合物含有伊曲康唑和磷酸、可药用载体和表面活性剂的熔凝混合物。
2.按照权利要求1的抗真菌组合物，其中在熔凝混合物中伊曲康唑和磷酸的重量比为1∶0.1至1∶10。
3.按照权利要求1的抗真菌组合物，其中所述可药用载体选自：乳糖、糊精、淀粉、微晶纤维素、羟丙甲基纤维素、羟丙基纤维素、羟乙基纤维素、乙基纤维素、甲基纤维素、聚乙二醇、二氧化硅、水滑石、硅酸镁铝、氢氧化铝、硅酸铝、硅酸镁铝、膨润土及其混合物。
4.按照权利要求1的抗真菌组合物，其中所述表面活性剂选自：聚氧乙烯乙二醇化的天然或氢化植物油、聚氧乙烯-脱水山梨醇-脂肪酸酯、聚氧乙烯脂肪酸酯、聚氧乙烯-聚氧丙烯嵌段共聚物、二辛基磺基琥珀酸钠、十二烷基硫酸钠、磷脂、丙二醇单-或二-脂肪酸酯、天然植物油甘油三酯和聚亚烷基多元醇的反式酯化的产物、单甘油酯、二甘油酯、单/二-甘油酯和脱水山梨醇脂肪酸酯。
5.权利要求1所述的抗真菌组合物的制备方法，该方法包括：
(a)将伊曲康唑和磷酸混合，
(b)将混合物加热至100至170℃得到均匀的熔融混合物，
(c)向其中加入可药用载体和表面活性剂，
(d)将形成的熔融混合物冷却得到固体，和
(e)将固体粉碎。
CNB008089485A 1999-06-16 2000-06-16 含有伊曲康唑的抗真菌口服组合物及其制备方法 Expired - Fee Related CN1170539C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990022472A KR100331529B1 (ko) 1999-06-16 1999-06-16 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
KR1999/22472 1999-06-16

Publications (2)

Publication Number Publication Date
CN1390127A true CN1390127A (zh) 2003-01-08
CN1170539C CN1170539C (zh) 2004-10-13

Family

ID=36441999

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008089485A Expired - Fee Related CN1170539C (zh) 1999-06-16 2000-06-16 含有伊曲康唑的抗真菌口服组合物及其制备方法

Country Status (18)

Country Link
US (1) US6039981A (zh)
EP (1) EP1185273B1 (zh)
JP (1) JP3717849B2 (zh)
KR (1) KR100331529B1 (zh)
CN (1) CN1170539C (zh)
AT (1) ATE324893T1 (zh)
AU (1) AU754300B2 (zh)
CA (1) CA2376706C (zh)
CZ (1) CZ292146B6 (zh)
DE (1) DE60027717T2 (zh)
ES (1) ES2262517T3 (zh)
HU (1) HUP0201533A3 (zh)
MX (1) MXPA01012739A (zh)
RS (1) RS50008B (zh)
RU (1) RU2216323C2 (zh)
SI (1) SI20677A (zh)
TR (1) TR200103681T2 (zh)
WO (1) WO2000076520A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294912C (zh) * 2004-03-01 2007-01-17 上海医药工业研究院 伊曲康唑盐酸盐组合物及其冻干粉针
CN108883087A (zh) * 2016-01-07 2018-11-23 R·马迪根 用于治疗南美锥虫病的组合物和方法
CN110755369A (zh) * 2019-10-30 2020-02-07 天津市保灵动物保健品有限公司 一种伊曲康唑软膏及其制备方法

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862463A1 (en) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
CA2291346A1 (en) * 1999-11-26 2001-05-26 Bernard Charles Sherman Antifungal solutions
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
IL156310A0 (en) * 2000-12-22 2004-01-04 Baxter Int Method for preparing submicron particle suspensions
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
KR100435141B1 (ko) * 2000-12-28 2004-06-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6673373B2 (en) * 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
EP1842532A3 (en) * 2001-02-06 2009-04-22 Stiefel Laboratories, Inc. Oral sparingly water-soluble antifungal formulations and methods of making the same
US6663897B2 (en) * 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) * 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
KR100441745B1 (ko) * 2001-11-30 2004-07-27 환인제약 주식회사 이트라코나졸의 경구투여용 조성물과 그 제조방법
US20040115266A1 (en) * 2002-02-01 2004-06-17 Namburi Ranga Raju Oral itraconazole formulations and methods of making the same
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
WO2004009120A1 (en) * 2002-07-22 2004-01-29 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1680091B1 (en) 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S A solid dosage form comprising a fibrate
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
JP2005239696A (ja) * 2004-01-30 2005-09-08 Daiichi Suntory Pharma Co Ltd 無機物質を配合した医薬硬質カプセル剤
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
CN1997372B (zh) * 2004-06-24 2010-06-02 西梯茜生命工学股份有限公司 包含依他康那唑的固态分散剂的制造方法及其医药组成物
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0612809D0 (en) * 2006-06-28 2006-08-09 Univ Sunderland Formulation
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
GB0714670D0 (en) * 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138561T1 (de) * 1992-02-12 1996-06-15 Janssen Cilag S P A Liposomale itraconazol formulierungen
WO1994016701A1 (en) * 1993-01-27 1994-08-04 Sepracor, Inc. Methods and compositions of (2s,4r) itraconazole for treating fungal yeast and dermatophyte infections
CA2154777A1 (en) * 1993-01-27 1994-08-04 Nancy M. Gray Method and composition employing (2r,4s) itraconazole
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
KR19990044257A (ko) * 1996-05-20 1999-06-25 디르크 반테 생체이용율이 개선된 항진균성 조성물
KR100321617B1 (ko) * 1997-06-16 2002-07-27 동아제약 주식회사 항진균제와 유기산류의 공융혼합물 및 이를 함유하는 약학적 제제
KR100367483B1 (ko) * 1997-12-19 2003-03-26 동아제약 주식회사 당류를이용하여용해도및용해속도를증가시킨이트라코나졸경구용조성물및그제조방법
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294912C (zh) * 2004-03-01 2007-01-17 上海医药工业研究院 伊曲康唑盐酸盐组合物及其冻干粉针
CN108883087A (zh) * 2016-01-07 2018-11-23 R·马迪根 用于治疗南美锥虫病的组合物和方法
CN110755369A (zh) * 2019-10-30 2020-02-07 天津市保灵动物保健品有限公司 一种伊曲康唑软膏及其制备方法

Also Published As

Publication number Publication date
CZ292146B6 (cs) 2003-08-13
AU754300B2 (en) 2002-11-14
EP1185273A1 (en) 2002-03-13
CA2376706C (en) 2006-06-06
JP2003501475A (ja) 2003-01-14
TR200103681T2 (tr) 2002-05-21
US6039981A (en) 2000-03-21
HUP0201533A2 (en) 2002-09-28
YU88601A (sh) 2004-07-15
JP3717849B2 (ja) 2005-11-16
AU5114400A (en) 2001-01-02
SI20677A (sl) 2002-04-30
HUP0201533A3 (en) 2006-07-28
EP1185273B1 (en) 2006-05-03
KR100331529B1 (ko) 2002-04-06
RU2216323C2 (ru) 2003-11-20
DE60027717D1 (de) 2006-06-08
MXPA01012739A (es) 2002-07-02
ES2262517T3 (es) 2006-12-01
CN1170539C (zh) 2004-10-13
EP1185273A4 (en) 2004-03-10
CZ20014508A3 (cs) 2003-03-12
RS50008B (sr) 2008-09-29
KR20010002590A (ko) 2001-01-15
CA2376706A1 (en) 2000-12-21
ATE324893T1 (de) 2006-06-15
WO2000076520A1 (en) 2000-12-21
DE60027717T2 (de) 2007-05-10

Similar Documents

Publication Publication Date Title
CN1170539C (zh) 含有伊曲康唑的抗真菌口服组合物及其制备方法
CN1213754C (zh) β－咔啉药物组合物
CN1165291C (zh) 具有改进的生物利用度的抗真菌组合物
CN1160079C (zh) 发泡性肠溶制剂
CN1121694A (zh) 含环孢菌素的粉末组合物
CN1607947A (zh) 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
CN1402629A (zh) 提供提高的药物浓度的药物组合物
CN1189161C (zh) 非结晶性头孢呋辛乙酰氧乙酯固体分散体、制备方法及其口服组合物
CN1886119A (zh) 泮托拉唑多颗粒制剂
CN1353613A (zh) 药物组合物
CN1180840C (zh) 含有环孢菌素的软胶囊制剂
CN1543359A (zh) 可生物利用的口服剂型醋氯芬酸组合物及其制备方法
CN1874767A (zh) 包含aplindore和其衍生物的缓释药物组合物
CN1256939C (zh) 含有辅酶q10的微乳剂预浓缩物和微乳剂
CN1744889A (zh) 坦洛新的控释药物组合物
CN1210065C (zh) 具有改善溶出性能的普仑司特的固体分散体系及其制备方法
CN1842331A (zh) 含有氨磺必利的新颖固体药物组合物
CN1791390A (zh) 口服的可持续释放的药用组合物
CN1228699A (zh) 提高生物利用度的抗真菌组合物
CN1662223A (zh) 含水溶性活性成分的球形微丸
CN101060862A (zh) 口服和直肠施用的组合物
CN1248691C (zh) 左西孟旦控释口服组合物
CN1726027A (zh) 包含曲马多和托吡酯的控释制剂
CN1193754C (zh) 释放控制型口服制剂
CN1161150C (zh) 药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041013

Termination date: 20120616